Archive for June 6th, 2012

ARIA MRK receive CRL. VVUS Qnexa MAA decision delayed. ABT NBIX initiate Phase 3 endometriosis. DYAX analysis of ecallantide due within 3 months + SGYP

Jun 06, 2012 No Comments by

Merck (NYSE: MRK) announced that the FDA issued a complete response letter (CRL) regarding the New Drug Application (NDA) for ridaforolimus for patients with metastatic soft tissue or bone sarcoma. The letter stated that additional clinical trial would need to be conducted to further assess safety and efficacy. ARIAD Pharmaceuticals, Inc (Nasdaq: ARIA) has a license […]

Daily News Read more